Nuvectis Pharma (NVCT) Cash from Operations (2021 - 2026)

Nuvectis Pharma has disclosed Cash from Operations across 6 years of filings, most recently posting 6511000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 6511000.0, down 55.99% year-over-year; the trailing twelve-month figure through Mar 2026 was 18346000.0 (down 52.08% YoY), and the FY2025 annual result was 16009000.0, down 30.72% from the prior year.
• Cash from Operations came in at 6511000.0 for Q1 2026 at Nuvectis Pharma, down from 3974000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 2404000.0 in Q3 2024 to a low of 6511000.0 in Q1 2026.
• The 5-year median for Cash from Operations is 3850000.0 (2023), against an average of 3781176.47.
• Across the five-year window, Cash from Operations tumbled 229.52% in 2022 and jumped 35.97% in 2024, its largest moves.
• Nuvectis Pharma's Cash from Operations stood at 3516000.0 in 2022, then slipped by 9.5% to 3850000.0 in 2023, then soared by 35.97% to 2465000.0 in 2024, then sank by 61.22% to 3974000.0 in 2025, then tumbled by 63.84% to 6511000.0 in 2026.
• The last three Cash from Operations figures came in at 6511000.0 (Q1 2026), 3974000.0 (Q4 2025), and 4494000.0 (Q3 2025), per Business Quant data.